{"schema_version":"secwatch.filing_event.v1","accession":"0001826667-25-000129","form_type":"8-K","ticker":"TLSI","cik":"0001826667","company_name":"TriSalus Life Sciences, Inc.","filed_at":"2025-08-29T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.171233+00:00","generated_at":"2026-05-17T09:17:41.733498+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"TriSalus Life Sciences raises CFO base salary to $550K, grants performance-based stock options","bullets":["CFO David Patience's annual base salary increased from $450K to $550K, effective immediately.","Compensation Committee approved stock options for 249,899 shares at $5.11 per share.","Options vest upon company achieving ≥$75M revenue in any 12 consecutive months by Dec 31, 2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001826667-25-000129","json":"https://secwatch.observer/filing/0001826667-25-000129.json","markdown":"https://secwatch.observer/filing/0001826667-25-000129.md","text":"https://secwatch.observer/filing/0001826667-25-000129.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1826667/000182666725000129/0001826667-25-000129-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1826667/000182666725000129/tlsi-20250825.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T09:17:41.733498+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}